Cellectis S.A. 6-K filed 2026-09-11

Cellectis S.A. filed a Form 6-K with the SEC on 2026-09-11. A 6-K is the report a foreign private issuer furnishes under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, and the cover page shows Cellectis files its annual reports on Form 20-F. The company lists its principal executive office at 8, rue de la Croix Jarry, 75013 Paris, France. The report is signed by André Choulika, Chief Executive Officer, and its only exhibit is 99.1, a press release dated September 11, 2026. The press release announces that Cellectis will host a conference call and webcast on Monday, September 14, 2026 to provide a business update. The English-language session is scheduled for 8:00 a.m. ET / 2:00 p.m. CET and the French-language session for 9:00 a.m. ET / 3:00 p.m. CET, each with its own webcast link. The release states that a replay will be available on the company's website after the event. For an analyst or journalist, the filing gives notice of a scheduled company update, not the update itself. The subject matter of the business update is not in the filing, and neither is any financial figure, clinical result, or other substantive disclosure. The release describes Cellectis as a clinical-stage biotechnology company that uses a gene-editing platform to develop cell and gene therapies, including allogeneic, off-the-shelf CAR T-cells for cancer patients, with in-house manufacturing and locations in Paris, New York and Raleigh, NC. The company trades on the Nasdaq Global Market under CLLS and on Euronext Growth under ALCLS. EDGAR classifies it under SIC description "Biological Products, (No Diagnostic Substances)" as an Accelerated filer. The investor relations contact named is Arthur Stril, Chief Financial Officer & Chief Business Officer, at investors@cellectis.com, and the full filing is available at the source URL.